Storia in 3 fonti

Chasing Vertex, Latigo reports non-opioid pain drug succeeds in key trial

Latigo Biotherapeutics' non-opioid LTG-001 reduced acute pain in Phase 2b, competing with Vertex's Journavx; Phase 3 trial planned for late 2026.

Raccontata da

Confronto fonti

3 prospettive sulla stessa storia

AI · summaries

endpoints.newsStai leggendo3 g fa

Latigo Biotherapeutics' non-opioid LTG-001 reduced acute pain in Phase 2b, competing with Vertex's Journavx; Phase 3 trial planned for late 2026.

Latigo Biotherapeutics published positive data for an acute-pain drug meant to rival a Vertex medicine already on the market